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Abstract
Background: Malaria in pregnancy is serious, and drug resistance in Africa is spreading. Drugs have greater risks in
pregnancy and determining the safety and efficacy of drugs in pregnancy is therefore a priority. This study set out to
determine the efficacy and safety of several antimalarial drugs and combinations in pregnant women with uncomplicated
malaria.
Methods: Pregnant women with non-severe, slide proven, falciparum malaria were randomised to one of 4 regimes:
sulfadoxine-pyrimethamine [SP]; chlorproguanil-dapsone [CD]; SP+amodiaquine [SP+AQ] or amodiaquine+artesunate
[AQ+AS]. Randomisation was on a 1:2:2:2 ratio. Women were admitted for treatment, and followed at days 7, 14, 21, 28 after
the start of treatment, at delivery and 6 weeks after delivery to determine adverse events, clinical and parasitological
outcomes. Primary outcome was parasitological failure by day 28.
Results: 1433 pregnant women were screened, of whom 272 met entry criteria and were randomised; 28 to SP, 81 to CD, 80
to SP+AQ and 83 to AQ+AS. Follow-up to day 28 post treatment was 251/272 (92%), and to 6 weeks following delivery 91%.
By day 28 parasitological failure rates were 4/26 (15%, 95%CI 4–35) in the SP, 18/77 (23%, 95%CI 14–34) in the CD, 1/73 (1%
95%CI 7–0.001) in the SP+AQ and 7/75 (9% 95%CI 4–18) in the AQ+AS arms respectively. After correction by molecular
markers for reinfection the parasitological failure rates at day 28 were 18% for CD, 1% for SP+AQ and 4.5% for AQ+AS. There
were two maternal deaths during the trial. There was no apparent excess of stillbirths or adverse birth outcomes in any arm.
Parasitological responses were strikingly better in pregnant women than in children treated with the same drugs at this site.
Conclusions: Failure rates with monotherapy were unacceptably high. The two combinations tested were efficacious and
appeared safe. It should not be assumed that efficacy in pregnancy is the same as in children.
Trial Registration: ClinicalTrials.gov NCT00146731
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Introduction
Malaria in pregnancy is an important preventable cause of
maternal and perinatal morbidity and mortality [1,2], and
contributes substantially to maternal morbidity in Tanzania and
elsewhere [3]. Pregnant women are at increased risk of clinical
disease compared with non-pregnant women [4,5]. In pregnancy,
women semi-immune to malaria carry substantial risks of severe
maternal anaemia and low-birthweight which is greatest in the first
pregnancy, and the malaria may be asymptomatic [6–8]. In
contrast, non-immune pregnant women, and possibly women with
HIV infection, are at a greater risk of premature delivery,
hypoglycaemia, severe anaemia, pulmonary oedema and maternal
death2.
The risks of malaria in pregnancy are therefore substantial both
to the mother and foetus. Using an effective antimalarial drug for
prevention and treatment is essential. Understandable concerns
are raised however by using any new drug in pregnancy; older
drugs have a better known safety profile in pregnancy, but are
likely over time to become less effective due to the emergence and
spread of drug resistance. Although there are no human data to
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suggest that artemisinins are teratogenic, animal data for use of
artemisinins early in pregnancy have raised concerns of teratoge-
nicity [9]. Traditional exclusion of pregnant women from clinical
trials has led to limited data on safety and efficacy of artemisinin
based combinations considered for general deployment especially
in Africa. Current practice of deriving malaria treatment policies
for pregnancy from data reporting efficacy of drugs in children is
inappropriate. Therefore, generating data on the efficacy and
safety of antimalarials in pregnancy is a priority [10,11]. This trial
was therefore designed to assess the efficacy and tolerability of two
antimalarial drug combinations and one novel form of monother-
apy in pregnant Tanzanian women.
Sulfadoxine-pyrimathamine (SP) has been assessed for safety in
pregnancy, is now recommended for intermittent preventive
treatment in pregnancy (IPTp), and remained Tanzanian national
policy for treatment until November 2006 and for Intermittent
Preventive Therapy in pregnancy in most countries (IPTp) to date
[12,13]. Amodiaquine (AQ) has been given to many hundreds of
women in pregnancy in Africa and elsewhere, either inadvertently
or deliberately, and studies have demonstrated no teratogenicity,
although formal safety data are sparse [14,15]. The WHO does
not consider that the combination of amodiaquine+artesunate in
pregnancy is contraindicated but evidence of its safety, in common
with other combinations, is sparse [16]. Chlorproguanil-dapsone
(CD) has proved effective as monotherapy in children in the
Muheza district (present study area) even when sulfadoxine-
pyramethamine was failing [17]. This drug provided a possible
choice of treatment for malaria in pregnancy at the time this trial
was planned. Experience with co-administered CD in pregnancy is
limited to its use as a single dose (chlorproguanil 1.2 mg/kg and
dapsone 2.4 mg/kg as a single dose), where it appeared safe [18].
Proguanil has been recommended for use as a safe antimalarial in
pregnancy for many years. Experience with dapsone treatment
during pregnancy used in Hansen’s disease (leprosy) and in other
pregnancy related conditions is reassuring [19]. Subsequent to this
trial CD has been withdrawn due to safety concerns in the CD-
artesunate (CDA) combination [20].
Despite concerns from animal studies both artesunate and
artemether have been given to many pregnant women (often
inadvertently), and current published data demonstrate no
evidence of human teratogenicity [21]. The WHO recommends
artemisinin derivatives can be used for malaria treatment during
the second and third trimesters of pregnancy in all settings and in
the first trimester where multi-drug resistance prevails and the
benefits outweigh the risks [22]. Whilst most of the data from
treatment doses is from Asia, 287 pregnant women in the Gambia
given a single dose of SP-artesunate had no increased rate of
adverse birth outcomes [23].
The present study compared the efficacy, tolerability and safety
of standard SP-monotherapy to CD that had been registered in
UK at the design of the study and to two drug combinations for
which good efficacy data was available from East Africa. AQ+SP
has proved effective both in Ugandan and Tanzanian children
[24,25], and in pregnancy in West Africa [26] and in some settings
proves better than artemisinin-based combinations [27]. AQ+AS
is first-line treatment in Zanzibar, and there is data on its efficacy
from several East African sites suggesting that it is significantly
more efficacious than amodiaquine monotherapy [21,28,29].
Methods
This open-label study was conducted among pregnant women
who attended Muheza Designated District Hospital (Muheza
DDH). The lowlands of Muheza district experience hyperendemic
to holoendemic malaria. The day 28 parasitological failure rates to
AQ monotherapy in a recent effectiveness trial in children under 5
years was 76%, with the comparative rates of 61% and 40% for
AQ+SP and AQ+AS21. Throughout the study period SP (defined
as monotherapy for the purposes of this paper) was national first-
line treatment for malaria, and this was taken as the comparator
arm for this study.
Pregnant women with mild-moderate, slide proven, falciparum
malaria were recruited from the Antenatal wing (ANC) of the
Reproductive and Child Health (RCH) clinic at Muheza
Designated District Hospital. Pregnant women from Muheza
Township and surrounding villages attend this clinic for their
medical care. Nurses at the RCH identified all febrile pregnant
women with a fever or recent history of fever (within 48 hours),
symptoms compatible with anaemia or malaria and referred them
to the study team. All referrals were re-interviewed and examined
by a medical officer from the study team to exclude concomitant
infection(s). Duplicate thick and thin blood smears were Giemsa
stained and examined microscopically for malaria parasites.
Inclusion criteria were pregnancy with either a positive blood
smear for P.falciparum with at least 800 asexual parasites/mL in an
asymptomatic woman or any of the following symptoms within 2
days prior to consultation; history of fever; headache, vomiting,
chills/rigors, and/or any of the following signs: temperature
$37.5uC and ,39.5uC, Hb$7 and ,9 g/dl) together with
P.falciparum parasitaemia at any density. Additionally, all cases had
to be 14–34 gestation weeks pregnant on the day of attending the
clinic, have a viable foetus defined by the presence of foetal
heartbeat by sonicaid or pinnard, able to take drugs orally, able to
attend follow up clinic, and gave written informed consent to
participate or a finger-print witnessed consent for women unable
to read.
The main exclusion criteria were; severe and complicated forms
of malaria [30], pregnancy in the first trimester or .34 gestation
weeks (because they had a high chance of delivering during the 28
day follow-up period), mixed plasmodial infection, complicated
pregnancy e.g. signs/symptoms of toxaemia, 2 or more abortions or
stillbirths, presence of concomitant disease masking assessment of the
response to treatment, intake of drugs contraindicated in pregnancy
or drugs with effective antimalarial activity within the last 2 weeks,
multiple gestation pregnancies, mother aged 38 years or above.
Withdrawal criteria were withdrawal of consent, appearance of other
species of Plasmodium or major protocol violation.
Women who met the inclusion criteria were randomised to one
of 4 regimes: three tablets of sulfadoxine-pyrimethamine (500 mg
sulfadoxine/25 mg pyrimethamine per tablet) orally at once [SP]
in line with the national policy; chlorproguanil-dapsone (1.2 mg/
kg and 2.4 mg/kg respectively for 3 days) [CD]; SP 3 tablets
once+amodiaquine (10 mg/kg for 3 days) [SP+AQ]; amodiaquine
(10 mg/kg for 3 days)+artesunate (4 mg/kg for 3 days) [AQ+AS].
Randomisation was on a 1:2:2:2 ratio for SP, CD, SP+AQ and
AQ+AS to maximise information about the drugs whose use in
pregnancy is less known; it was assumed the difference in outcome
would be greatest for SP compared to other arms so the size of this
arm could be smaller. Randomisation was in blocks of random
sizes, and conducted in London using Stata 7. Treatment
allocations were placed in a sealed opaque envelope, with
pregnant women picking their own envelope. Patients were
allocated a study number sequentially, and after consenting to
participate, participants picked an envelope in front of the
attending clinician. Opening the envelope constituted entry to
the trial and analysis was conducted on that basis (defined as
analysis of all cases in which there was an outcome, irrespective of
actual treatment given).
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All women were admitted to a ward dedicated to research for
the first three days to facilitate supervised drug administration and
to monitor clinical response and adverse events. Drugs were
administered by study nurse-midwives employed by the project.
After each administration, the patient was observed for 45–
60 minutes. The dose was repeated if vomiting occurred within
the observation period. Vomiting the second dose was registered
as an adverse event and led to withdrawal from the study. Such
cases were treated with parenteral quinine. Patients were treated
for symptoms with standard medications e.g. paracetamol for
fever. Women continued to receive routine antenatal medicaments
of iron supplements, folic acid (5 mg), and tetanus toxoid (TT)
given by the RCH. In addition to daily clinical observations and
laboratory tests, foetal viability (presence of foetal heartbeat) was
monitored daily during admission using a Doppler machine, and
at each follow-up visit.
Adverse events were classified by severity and potential causal
relationship to study drugs. All serious adverse events (SAEs) were
independently investigated by a local safety monitor. Subjects with
an AE were followed up until the condition had disappeared or
stabilized.
Parasite counts on Giemsa-stained blood films were performed
daily during admission, repeated on days 7, 14, 21 and 28, and on
any other day(s) of complaints. Counts were made against 200
white blood cells (WBC) on a thick blood smear. All slides had a
second reading done in an independent research laboratory.
Discordant results were read by a third reader, with the majority
taken as the definitive outcome. All microscopists were blind to
treatment allocation. A separate read for gametocytes was
undertaken counting against 500 white blood cells. To quantify
the effect of treatment on gametocyte carriage, we determined the
area under the curve (AUC) of gametocyte density over time
which incorporates both the magnitude and the duration of
gametocyte carriage [31].
Blood samples for haematology and clinical chemistry, and in
anaemic women stool microscopy for intestinal helminths were
obtained on admission. Blood and urine samples were repeated at
day 3 and where indicated at day 7. Haemoglobin, total and
differential white blood cell count, platelet count, creatinine, total
bilirubin, alanine aminotransferase (ALT) and albumin were
measured (using CBC machine for haemogram and Reflectron for
biochemistry) on days 0, 3 and 7, and whenever else indicated.
Pre-test counselling for HIV-testing was undertaken, and where
consent was given an HIV test was performed. HIV-positive
mothers were referred to the HIV care unit of Muheza DDH for
counselling and for consideration of antiretroviral drugs.
On discharge from the ward, patients were followed up on days
7, 14, 21 and 28 post initiation of treatment and at any time they
felt unwell before day 28. At the end of each clinic, members of the
study team followed all non-attendees to their homes to establish
and record reasons for non-attendance and to collect a blood
smear. Patients with either early or late treatment failure following
treatment with any of the 4 study regimens were treated with
quinine 10 mg/kg 8 hourly for 7 days as rescue therapy.
Birth outcome and Dubowitz assessment were recorded for all
deliveries taking place at the hospital. Mothers and their newborns
attended follow up clinics 6 weeks after delivery. All non-attendees
(whether delivered at Muheza DDH or not) were followed up at
home. Assessment at this time included a further check of the
newborn by the paediatrician for any abnormality that may have
been missed at birth or for any serious problem that may occur
after birth such as kernicterus. Whenever the mother had moved
from the study area, all possible efforts were made to ascertain
birth outcome verbally from close relatives. A DSMB reviewed all
SAEs, which were notified as they occurred.
Blood for PCR was collected on glass-fibre membranes from all
patients at enrolment and at each follow-up. The polymorphic
repetitive regions were amplified by nested-PCR for block 3 of
msp2 [32]. Using the template of the first PCR reaction, allele-
specific primer pairs was used to test for the presence of the allelic
variants from FC27 and IC of the families of the msp2 region.
Amplification patterns of the various allelic families in DNA
samples from day 0 were compared to other samples from the
same patient when parasitaemic. If the allelic family(ies) amplified
on day 0 included those which were identical in size to those
amplified during a subsequent episode, then the patient was
classified as carrying a recrudescent infection.
The primary end-point of the trial was parasitological failure by
day 28. This was defined as any of: a need for rescue treatment
due to clinical deterioration defined by altered sensorium, seizures,
persistent vomiting, renal impairment, respiratory distress, a fall in
Hb below 7 g/dl, or in cases where the initial haemoglobin
dropped 20% or more from baseline Hb, at any time during
admission; persistence of fever with parasitaemia on day 3;
increased parasite density on day 2 or 3 compared with baseline
density; failure to clear parasites on day 7; rescue medication for
recurrent malaria before day 28; slide parasite positivity at day 14,
21 or 28.
Major secondary endpoints were: clinical failure by day 28
(parasitological in the presence of symptoms compatible with
malaria), parasitological or clinical failure by day 14, incidence of
foetal death during treatment, defined as absence of foetal
heartbeat assessed by Doppler; change in haemoglobin from
baseline on day 14; incidence of perinatal and neonatal mortality,
assessed 4–6 weeks after due date of delivery; clinically apparent
neonatal abnormality 4–6 weeks after due date of delivery;
preterm delivery and other adverse events during treatment.
Initially the study was powered to detect a 4 fold difference in
treatment failure between SP+amodiaquine and amodiaquine+ar-
tesuante groups (8% vs 2%) with 95% precision and 80% power,
which would require a samples size of 80 women in the SP+placebo
group and 240 women in each of the other three groups. Vigorous
measures to protect pregnant women in the district from malaria on
a general background of reduced transmission of malaria in this area
fortunately led to substantial reductions in the number attending the
antenatal clinic with clinical malaria. The data from this and other
sites was reviewed onOctober 2004 and it was decided that given the
absence of other data, the question was important enough and of
sufficient public health priority that a trial able to detect a larger
difference would still be of public health importance. A revised
sample size was calculated to detect a difference from 1% (the best
likely failure rate in any arm) and 15% (above which no drug could
be deployed). This gave a sample size of 72 in each arm when a was
.05 and b 0.8. The unbalanced sample size (1:2:2:2) was by this time
established and could not be revised retrospectively although the
statistical rationale for it was not present with the revised design.
Data were double entered into Microsoft Access, and analysed
using Stata 8. The analytical plan was finalised before the analysis
was undertaken. For primary and major secondary outcomes,
proportions with confidence intervals were calculated. Odds ratios
were calculated for the difference between all arm and the best and
worst arms for parasitological failure unadjusted, and adjusted for
the predefined risk factors age, parity, HIV serostatus, initial
parasitaemia and initial haemoglobin.
Ethical permission was granted by the ethics committees of the
National Institute for Medical Research, Tanzania, and the
London School of Hygiene & Tropical Medicine and conducted in
Antimalarials in Pregnancy
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accordance with the Declaration of Helsinki. All participants gave
written informed consent (or witnessed where whey could not
read). The trial was monitored by an independent external clinical
monitor and was prospectively registered on ClinicalTrials.gov
No. NCT00146731. The protocol for this trial and supporting
CONSORT checklist are available as supporting information: see
CONSORT S1 and Protocol S1.
Results
The trial ran from Jan 2004–Sept 2006. 1433 pregnant
women were screened, of whom 272 were enrolled, 28 to the SP,
81 to the CD, 80 to the SP+AQ and 83 to the AQ+AS arms
respectively. The slight variation from the planned 1:2:2:2
randomisation was due to random variation in the smallest arm
because the trial did not reach the originally planned sample size
on which the randomisation was based. Reasons for exclusion
and flow through the trial are outlined in Fig. 1. The patients
were similar at baseline (Table 1) and the prevalence of markers
associated with antifolate resistance was high in all baseline
samples (DHFR 51I+59R+108N= 96.2%; DHPS S436+437G+
540E= 92.0%). Follow-up to day 28 post treatment was 251/272
(92%), and to 6 weeks following delivery 91%. Almost all those
lost to follow-up were confirmed as having moved out of the
study area.
Figure 1. Flow through the trial. Data not adjusted for PCR correction. *Other includes living out of study area, multiple pregnancy, masking
disease. Returned: returned to study area; no intercurrent treatment (d0–d28). SP = sulfadoxine-pyrimethamine AQ= amodiaquine CD= chlorpro-
guanil-dapsone AS= artesunate. d14=day 14 post-randomisation d28 =day 28 days post-randomisation; 6w post-del = 6 weeks post delivery.
doi:10.1371/journal.pone.0005138.g001
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By day 14, the parasitological failure rates (including both
symptomatic and asymptomatic cases) were 1/24 (4%) in the SP,
1/78 (1.3%) in the CD, 0/71 (0%) in the SP+AQ and 0/77 (0%)
in the AQ+AS arms respectively. By day 28 the equivalent
parasitological failure rates were 4/26 (15%, 95%CI 4–35) in the
SP, 18/77 (23%, 95%CI 14–34) in the CD, 1/73 (1% 95%CI
0.001–7) in the SP+AQ and 7/75 (9% 95%CI 4–18) in the
AQ+AS arms respectively. After correction by molecular markers
for reinfection, the parasitological failure rates at day 28 were 18%
for CD, 1% for SP+AQ and 4.5% for AQ+AS; numbers in the SP
arm were considered too small to be reliable. Full data are shown
in Table 2. Adjusted and unadjusted odds ratios comparing each
Table 1. Baseline characteristics in the four arms.
SP CD SP+AQ AQ+AS
Number 28 81 80 83
Median age in years (IQR) 21 (19–26) 21 (19–27) 20 (19–25) 21 (19–26)
Median gestation in months (IQR) 6 (5–8) 7 (6–8) 7 (5–7) 6 (5–7)
Mean haemoglobin g/dL (SD) 9.3 (1.3) 9.6 (1.2) 9.0 (1.3) 9.3 (1.3)
Median parasite count (/200 WBC) 184 (55–535) 106 (23–650) 25 (51–578) 181 (62–628)
Median days unwell 3 3 3 3
% with primary education 93 90 85 91
Gametocytes at presentation (%) 23% 20% 17% 12%
DHFR triple mutation; N = 131* (51I+59R+108N) 83.3% (10/12) 94.7% (36/38) 100% (46/46) 97.1% (34/35)
DHPS double mutation; N = 137 (S436+437G+540E) 92.3% (12/13) 89.2% (33/37) 97.9% (46/47) 85.0% (34/40)
DHFR Triple+DHPS double; N = 119 81.8% (9/11) 82.4% (28/34) 97.7% (42/42) 93.5% (29/31)
HIV test positive (%) 0/27 1/80 (1.3) 1/82 (1.2) 0/79
Primiparous** (%) 7/12 (58) 26/42 (62) 14/38 (39) 20/34 (59)
*Some samples for PCR were lost in transit from field to laboratory.
**Parity was not recorded for the initial study participants.
doi:10.1371/journal.pone.0005138.t001
Table 2. Clinical and parasitological outcomes by days 14 and 28 after treatment.
SP CD SP+AQ AQ+AS
Clinically relevant outcomes
Number assessed by day 14 24 78 71 77
Clinical failure by day 14 (%). 0 1 (1.3) 0 0
Parasitological failure by day 14 (%). 1 (4) 0 0 0
Adequate clinical and parasitological response (ACPR) by day 14 (%) 23 (96) 77 (99) 71 (100) 77 (100)
Mean haemoglobin (g/dL) at day 14 (SD). 9.1 (1.2) 9.3 (1.1) 8.9 (1.2) 9.1 (1.2)
Median change Hb (g/dL) from baseline (IQR) 20.2 (20.8 0.3) 20.25 (2.85 0.3) 0.10 (2.05 0.4) 20.3 (20.6–0.3)
Largest drop in Hb by day 14 (g/dl) 21.6 23.2 23.0 23.3
Number assessed by day 28 26 77 73 75
Clinical failure by day 28 (%) 1 (4) 11 (15) 0 1 (1)
Parasitological failure by day 28 (%) 3 (12) 7 (9) 1 (1) 6 (8)
Adequate clinical and parasitological response, day 28. (% and 95%CI) 22 (85%, CI 65–96) 59 (77%, CI 66–86) 72 (99% CI 92–100) 68 (91% CI 82–96)
Failures due to recrudescence if those replicating up (to day 28) 0/3 7/9 1/1 2/4
Clinical or parasitological failure rate by day 28 after correction of reinfection. 0 (Numbers small) 18% 1% 4.5%
Failures showing DHFR triple+DHPS double mutation; N = 25 (to day 28) 50.0% 64.3% 0% 66.7%
(2/4) (9/14) (0/1) (4/6)
Recudescences showing DHFR triple+DHPS double mutation; N = 10
(to day 28)
0% 85.7% 0% 50%
(0/0) (6/7) (0/1) (1/2)
Gametocytes
Prevalence day 14% (N assessable) 19.1 (21) 25.0 (64) 7.9 (63) 4.7 (64)
Mean AUC of gametocyte density/uL over time, (IQR) 24.4 (4.0–135) 36.2 (11.9–115.5) 20.5 (6.0–63.4) 8.1 (4.0–16.0)
doi:10.1371/journal.pone.0005138.t002
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arm with the best and worst arms (AQ+AS and SP respectively)
are shown in Table 3. Relative risks are also shown for comparison
with trials which do not use OR. Clinical and parasitological
outcomes for AQ+SP and AQ+AS were significantly better than
for SP or CD. Although there was a significant parasitological
failure rate, both for monotherapy and the combinations the
parasitological responses among pregnant women were substan-
tially better than among children under 5 years in the same site 2
years prior to the current study (Fig 2).
At day 14, restricting data to patients with no gametocytes at
baseline, 5/16 women (31%) in the SP arm, 12/50 (24%) in the
CD arm, 5/54 (9%) in the SP+AQ arm and 3/56 (5%) in the
AQ+AS arm were gametocytaemic (Fig 3). The odds ratio of
gametocytes in the AQ+AS arm compared to other arms was
therefore 0.12 (95%CI 0.02–0.78 p0.004) for SP, 0.18 (95%CI
0.03–7.4 p0.006) for CD and 0.55 (OR 0.08–3, p0.4) for AQ+SP.
There were two maternal deaths during the trial. One woman
in the CD arm had mild malaria both clinically and
parasitologically when she entered the trial, but developed
hyperparasitaemia (.20% parasitaemia) and severe malaria over
48 hours. Review of initial blood films showed that the initial
parasite count was correct, but all parasites were synchronous
pre-schizonts. She came from a mountain area with little malaria
transmission. The second woman in the SP+AQ arm made an
initial response but then deteriorated despite clearing her
parasites. Consent for determining her HIV serostatus was not
given, but other clinical factors suggest it is likely she died from
an immunosupression related illness. In neither case was the
direct effect of study drugs thought likely to have been the cause,
although CD may have failed to stop progression of severe
disease in the first case. No other maternal SAEs were recorded;
non-severe maternal adverse events are recorded in Table 4.
There were minor biochemical, haematological and ECG
abnormalities following administration of drugs outlined in
Table 5, but no clear patterns except possibly a small increase
in prolonged QTC interval of less than 500 milliseconds in the
SP+AQ arm; all resolved.
No foetal deaths occurred within 28 days of administration of
drugs except in the two women who died. There was one
macerated stillbirth in the AQ+AS arm. Other adverse birth
outcomes, largely relating to complications related to asphyxia are
shown in Table 4, along with caesarean section rates and outcome
at 6 weeks following birth. There were 15 stillbirths or deaths
within 48 hours of delivery. In the SP arm there was one
premature delivery at 27 weeks; the baby died at 32 hours. For
CD there was a stillbirth to a 40 year old HIV positive woman, 2
neonatal deaths, one in a twin at 30 weeks, the other in a case of
abruption placenta. Two babies died within 24 hours following
prolonged labour, and there was one death following obstructed
labour. In the SP+AQ arm there was one intrauterine death, two
deaths in twins who dies after home delivery, and a child failed to
control the neck at 6 weeks secondary to prolonged second stage of
labour. In the AQ+AS arm there was a breech birth of a
macerated baby at 40 weeks, a stillbirth at term, a intrauterine
death and a stillbirth in a twin, the other surviving. Other SAEs at
or following birth were: one baby an extra digit each hand;
SP+AQ one child with encephalopathy (probably ischemic), one
with peupural sepsis, one born with slow reflexes at birth, resolved
by 6 weeks, one jaundiced at birth resolved at 6 weeks; AQ+AS
one baby hyperpigmented at birth, resolved. Four of the deaths
were in twins which had not been identified at admission. There
were additionally 3 sets of twins, one in each of the CD, SP+AQ
and AQ+AS arms which had normal deliveries.
Figure 2. Day 28 parasitological failure rate (%), in pregnant
women compared with children from the same site.* Data on
children from Mutabingwa TK et al. Amodiaquine alone, amodiaqui-
ne+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and arte-
mether-lumefantrine for outpatient treatment of malaria in Tanzanian
children: a four-arm randomised effectiveness trial. Lancet.
2005;365:1474–80. Unadjusted for PCR correction, study in children
.5 years 2003–4.
doi:10.1371/journal.pone.0005138.g002
Table 3. Difference in parasitological outcomes between the arms- unadjusted and adjusted for age, gestation, initial parasitaemia
and haemogobin.
Unadjusted odds ratios
(95%CI) Sig p
Adjusted odds ratios
(95%CI) Sig p
Unadjusted relative risk
((95%CI))
AQ+SP v AQ+AS 0.13 (0.02–1.1) 0.06 0.13 (0.015–1.1) 0.06 0.15 (0.02–1.2)
AQ+SP v SP1 0.08 (0.005–0.7) 0.025 0.06 (0.006–0.6) 0.02 0.09 (0.01–0.76)
AQ+SP v CD2 0.046 (0.006–0.36) 0.003 0.046 (0.005–0.36) 0.004 0.06 (0.008–0.43)
AQ+AS v SP 0.56 (0.15–2.1) 0.4 0.61 (0.16–2.4) 0.47 0.61 (0.19–1.9)
AQ+AS v CD3 0.34 (0.13–0.86) 0.02 0.36 (0.14–0.94) 0.04 0.40 (0.18–0.90)
SP v CD 0.60 (0.18–2.0) 0.4 0.57 (0.16–2.0) 0.4 0.66 (0.2–1.8)
Best arm first in each pairwise comparison, without PCR adjustment.
1AQ+SP significantly better than SP.
2AQ+SP significantly better than CD.
3AQ+AS significantly better than CD.
doi:10.1371/journal.pone.0005138.t003
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Discussion
Balancing the risk-benefit of antimalarial drugs in pregnancy is
not easy [33]. Older drugs have a better known safety profile in
pregnancy, but parasite resistance to them is likely to be higher
than for new drugs and combinations. In this trial, conducted in an
area of known moderate to high rates of drug-resistant malaria
both to SP and AQ, the combinations AQ+SP and AQ+AS were
more efficacious than either SP or CD monotherapy in pregnant
women, although probably because the SP arm was small the
difference between SP and AQ+AS was non-significant. Dizziness
that was common in AQ-based combinations may be due to
transient hypotensive tendencies [34]. There is no evidence that
either of the drug combinations was less well tolerated than
monotherapy, except in minor gastrointestinal side effects. The
artemisinin combination AQ+AS was not associated with any
detectable increase in adverse birth outcomes when used in the last
two trimisters of pregnancy. Malaria in pregnancy is a very serious
disease for both mother and fetus; effective treatment is essential.
In this area of East Africa the two drug combinations can therefore
be recommended for treating proven malaria in pregnancy.
CD had a similar failure rate to SP, a difference from the results
of a similar study conducted in children under five years of age in
the same area 5 years ago, where CD treated malaria that had
failed to respond to SP22. It is possible that the dose of
chlorproguanil that was used in CD was not high enough to
attain adequate therapeutic levels in pregnancy. It was one of
two generally used dosing regimens, the other being one based
on 2 mg/kg chlorproguanil per day. The lower dose was chosen
because of fear of possible risk of drugs in pregnancy, and a
Figure 3. Prevalence of gametocytes, by study drug and day after treatment. SP- sulfadoxine-pyrimethamine. SP+AQ- sulfadoxine-
pyrimethamine+amodiaquine. AQ+AS amodiaquine+artesunate. CD- chlorproguanil-dapsone.
doi:10.1371/journal.pone.0005138.g003
Table 4. Adverse events by day 28, Serious Adverse Events (SAEs) and birth outcomes at 6 weeks post-delivery by study drug.
Drug (n) SP (28) CD (81) SP+AQ (80) AQ+AS (83)
Non-serious adverse events
Nausea/vomiting (%) 3 20 33 35
Abdominal pain 1 6 0 4
Diarrhoea 0 9 0 2
Dermatological, including itching (%) 0 2 10 2
Dizziness 1 1 7 7
Respiratory complaints 0 2 0 3
Birth outcomes
Mean weight at delivery, Kg (SD) 3.0 (0.6) 3.1 (0.5) 3.0 (0.7) 3.2 (0.6)
Median weight of placenta, Kg 0.56 0.56 0.56 0.53
Caesarean sections (%) 1 1 1 3
Minor abnormal birth outcomes (%) 6/26 (23%) 13/74 (18%) 14/75 (19%) 15/79 (19%)
Minor abnormality at 6 weeks 3 7 8 3
Major abnormality at 6 weeks 0 0 0 0
doi:10.1371/journal.pone.0005138.t004
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higher dose might have proved more effective [35]. Earlier
pharmacokinetic studies during pregnancy in Thailand
showed that doubling the recommended dose of proguanil was
required to attain similar blood drug concentrations in a non-
pregnancy state [36,37]. An alternative is that antifolate
resistance has increased still further in this area. With the recent
withdrawal of CD following concerns about anaemia with the
CDA combination, it is unlikely CD will be available for use in
pregnancy; on this evidence it would not be an appropriate drug
for use in pregnant women in coastal East Africa at the current
dose.
It is encouraging, as seen in Fig 2, that despite the exceptionally
high parasite resistance rates to AQ and SP in children in this area
of Tanzania, combinations using these drugs are comparatively
efficacious in pregnant women, and this is backed up by data from
the very different epidemiological setting of West Africa [38]. The
current trial is the second time the SP+AQ combination has been
shown to be efficacious in pregnant women in Africa, the other
being a previously reported trial from Ghana [26]. For policy this
should be interpreted with caution in this area; in East Africa this
initially efficacious combination rapidly lost its efficacy in children.
This, however, makes clear the limitations of using data on drug
efficacy in children to derive drug treatment policies in pregnant
women, and it strengthens the fact that combinations containing
older drugs which are losing efficacy in children may still remain
efficacious in pregnancy. This is especially important in the case of
IPTp, for which drugs must have a proven safety record as they
will frequently be given to women who are not parasitaemic
[39,40]. This means that the risk-benefit is less heavily weighted in
favour of using a highly efficacious but potentially teratogenic drug
than is the case in parasitologically proven cases.
As in children, the artemisinin-based combinations had a far
greater impact on gametocyte carriage than non-artemisinin
combinations, even when (as was the case with SP+AQ) the drug
combination was itself highly efficacious. The relative immunity
which is the likely cause of the different impact on efficacy between
pregnant adults and children does not seem so marked for
gametocytes. This is potentially important when considering the
likely impact of ACTs on transmission, since a substantial
proportion of the transmission of malaria is from adults.
Tanzania has a moderate prevalence of HIV in pregnancy, but
unfortunately the numbers in this trial are not big enough to answer
the question as to which drugs are likely to be most appropriate in
HIV-infected pregnant women. There is a complex interaction
between HIV and malaria in pregnancy; HIV both increases the
risks of side-effects of some drugs and reduces the efficacy of
antimalarials [41,42]. Multi-centre and multi-site clinical drug trials
in pregnancy, coupled with HIV testing, are urgently needed to
determine drug response in HIV-infected pregnant women with
consequent development of appropriate drug policies.
This study adds to the existing data, mostly from studies in
Southeast Asia, demonstrating no evidence of teratogenicity when
artemisinins are used in the last two trimesters. This is reassuring
now that ACTs are being rolled out. It cannot settle the question
about the safety of artemisinins early in the first trimester, which is
the period that has raised most concern on safety in animal studies.
There is no evidence from human studies that artemisinins are
teratogenic, but data is still too sparse to rule this out. It may be
that non-artemisinin combinations, especially for IPTp, remain a
sensible option in some settings for the interim. The investigators
decided at the outset of the trial not to study artemether-
lumefantrine (Coartem), despite being an excellent antimalarial,
because there was no data on safety in African pregnant women.
One study conducted in Thailand indicated that the pharmaco-
kinetics of Coartem is deranged in pregnancy [43].
The major limitations of the study are the fact that the size was
smaller than anticipated, and that women without typical symptoms
of malaria are likely to be under-represented (as they do not present),
and women with placental malaria but no peripheral parasites by
definition cannot be included. Bias is unlikely to be a major issue as
this is a randomised trial, although in smaller trials important
random variations between arms can occur.
Despite the fact that the sample size is small for definitive
conclusions on safety, it is reassuring both that newer drugs and
combinations, including the artemisinin combinations, are toler-
able and efficacious in pregnant women in East Africa. In this
area, monotherapy with SP or CD for malaria in the last two
trimesters of pregnancy, whilst it has antimalarial parasitological
failure rates substantially lower than in children, is unacceptably
high and should be abandoned. The risks of malaria in pregnancy
Table 5. Biochemical, haematological and ECG changes by drug class.
SP CD SP+AQ AQ+AS
Median AST day 0 U/l (IQR) 9.7 (8.6–13.4) 9.6 (7.2–12.8) 10.1 (7.8–13.5) 9.2 (7.2–12)
Median AST day 3 U/l (IQR) 9.2 (7.7–12.7) 12.7 (8.1–18) 9.7 (6.8–12.3) 8.8 (6.8–11)
Cases with AST .50 U/l day 3 (concentrations) 0 2 (64.6, 83) 1 (58.3) 0
Platelets6109 L21 day 0 (IQR) 123 (104–171) 165 (112–191) 154 (123–195) 165 (112–191)
Platelets6109 L21 day 3 (IQR) 179 (142–216) 170 (112–198) 171 (144–212) 170 (112–198)
Cases with platelets ,506109 L21 d 3 (absolute counts). 1 (47) 0 0 0
Neutrophils6109 L21 day 0 (IQR) 3.2 (2.3–3.8) 3.1 (2.3–4.1) 3.1 (2.3–4.3) 3.5 (2.3–4.2)
Neutrophils6109 L21 day 3 (IQR) 2.8 (1.3–4) 3 (1.9–3.9) 2.9 (2.2–3.9) 3.1 (2.3–4.1)
Neutrophils ,0.56109 L21 day 3 (count) 0 2 (0.4, 0.4) 1 (0.2) 2 (0.1, 0.4)
ECG QCT interval ms day 0 (IQR) 426 (414–441) 422 (410–441) 428 (411–443) 424 (415–433)
ECG QTC interval ms day 3 (IQR) 422 (411–438) 423 (407–437) 427 (415–445) 426 (411–434)
ECG QTC interval .440 ms 4 18 8 9
ECG QTC interval .500 ms 0 0 0 0
IQR- Inter Quartile Range.
doi:10.1371/journal.pone.0005138.t005
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are too great to continue to use drugs with appreciable
parasitological failure rates.
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